Abstract:Purpose The purpose of this paper is to examine the factors affecting profitability of pharmaceutical company in Indonesia. While research and development has been the main discussed issues in pharmaceutical sector development, scant attention has been paid to profitability factors determined by financial ratio specifically. The industry itself faces significant disruption with the implementation of universal health coverage in Indonesia. This study investigates the factors affecting profitability in an Indonesian pharmaceutical company after the national health insurance policy implementation. Design/methodology/approach This research is based on five independent variables (IVs) with six measurements that were empirically examined for their relationship with profitability. These variables are firm size (as measured by total sales), company efficiency (assets turnover), liquidity (current ratio), market power (the Lerner index) and a firm's growth (as measured by sales growth and sustainable growth rate). Data of ten pharmaceutical companies listed on the Indonesia Stock Exchange covering the period of 2014–2018 were extracted from companies' annual reports. Pooled ordinary least squares regression and fixed effects were used to analyze the data. Findings The findings show strong and positive relationships between liquidity and sustainable growth rate with profitability as measured by return on equity (ROE), return on assets (ROA) and earning per share (EPS), except EPS for liquidity. Further, both firm size and market power show positive significant relationships with ROA but negative significant relationships with EPS. Sales growth and company efficiency (as measured by assets turnover ratio) have no significant relationship with profitability. Research limitations/implications Due to data availability, the data include only listed pharmaceutical companies in the Indonesia Stock Exchange. Practical implications These results benefit internal users (such as managers, shareholders and employees). They can realize the determinants of enhancing the profitability of their company after the implementation of universal health coverage from the Indonesian government (JKN – Jaminan Kesehatan Nasional) since 2014. On the other side, other external users (such as investors, creditors, newly established pharmaceutical companies and tax authorities) also may get advantages of these results. It is clear that a significant impact happened upon this new policy implementation, and how an Indonesian pharmaceutical company will be profitable in the future. The relevance of company's business strategy (product and customer portfolio, competitor intelligence, etc.) with the profitability factors from this study can be further scrutinized as further consideration for both internal and external users. Originality/value This study differs from previous studies in many ways; first, it focuses on pharmaceutical companies in Indonesia. Previous studies have concentrated on different countries and companies in other sectors, such as services, banking and financial institutions or on industrial organizations. Second, this study analyzes the data from pharmaceutical companies' annual reports since 2014. There was a significant event of universal health coverage (national health insurance) implementation from the Indonesian government. Third, the study used ROE, ROA and EPS as indicators of profitability. Last but not least, the results of the study provide empirical evidence that firms with significant market power, good liquidity and well-managed sustainable growth rate improve operating income and ultimately enhance profitability.

FINANCIAL HIGHLIGHTS COMPARISON OF THE PHARMACEUTICAL INDUSTRY BEFORE AND DURING THE PANDEMIC PERIOD : 2018-2021 ANALYSIS

Impact of the Covid 19 Pandemic on the Financial Performance of Consumer Goods Industry in 2019-2020 on the Indonesia Stock Exchange

Comparative Analysis of the Financial Performance of the Food and Beverage Industry before and during the Pandemic Period

ANALISIS KINERJA KEUANGAN PT. KIMIA FARMA TBK DENGAN PT. INDOFARMA TBK SEBELUM PANDEMI DAN PADA SAAT PANDEMI COVID-19

Company's Financial Performance Before and During the Covid-19 Pandemic on the Indonesia Stock Exchange

ANALYSIS OF THE FINANCIAL PERFORMANCE OF FOOD AND BEVERAGE COMPANIES BEFORE AND DURING THE COVID-19 PANDEMIC IN INDONESIA

ANALYSIS OF PROFITABILITY, WORKING CAPITAL, INVENTORY BEFORE AND AFTER THE COVID-19 PANDEMIC: EMPIRICAL STUDY FROM THE PHARMACEUTICAL INDUSTRY

Corporate Policy Strategy Based on Comparison of Financial Performance Due to the Impact of the Covid-19 Pandemic

The Covid-19 Pandemic's Impact On Financial Performance And Market Performance In Nine Indonesian Business Sectors

ANALYSIS OF FINANCIAL PERFORMANCE USING LIQUIDITY RATIO, SOLVENCY RATIO, ACTIVITY RATIO, PROFITABILITY RATIO IN PHARMACEUTICAL SUB-SECTOR MANUFACTURING COMPANIES ON THE INDONESIA STOCK EXCHANGE FOR THE 2018-2020 PERIOD IN DKI JAKARTA

Factors Affecting Value of Companies (Case Study of The Indonesian Pharmaceutical Industry)

Performance Analysis of Mining Companies Listed on the Indonesia Stock Exchange Before and During the Covid-19 Pandemic for the 2018-2021 Period

Kinerja Keuangan Sebelum dan Masa Pandemi Covid-19 Pada Perusahaan BUMN

An Analysis of Financial Performance of Pharmaceutical Industry in India - A Study on NSE Listed Pharmaceutical Companies

Factors affecting profitability of pharmaceutical company: an Indonesian evidence

Financial Performance Analysis Before And After Acquisition and its Impact on Sustainable Growth Rate in the Pharmaceutical Industry

COMPARISON ANALYSIS OF LOCAL GOVERNMENT FINANCIAL PERFORMANCE BEFORE AND DURING THE COVID-19 PANDEMIC AND ITS IMPACT ON ECONOMIC GROWTH

The Impact of Financial Ratios on Return on Asset, Moderated by Total Assets: A Study on Pharmaceutical Companies in Indonesia

FINANCIAL PERFORMANCE ANALYSIS OF CONSTRUCTION COMPANY BEFORE AND DURING COVID-19 PANDEMIC IN INDONESIA

Financial Performance Analysis of Pharmaceutical Industry in India

FINANCIAL PERFORMANCE ANALYSIS OF STATE OWNED AND PRIVATE ENTERPRISES IN PHARMACEUTICAL INDUSTY LISTED IN INDONESIA STOCK EXCHANGE IN PERIOD YEAR 2012 - 2016